About Us Services Careers FAQ Contact Us 0
Home Pharmaceuticals IVD Raw Materials Market Size, Global Trends, Top Share, Forecast 2033
IVD Raw Materials Market
Select Regional / Country Report
Global North America Asia Pacific Europe United States Germany Japan France China India

IVD Raw Materials Market Size, Share & Trends Analysis Report By Product Type (Antibody, Antigens, Proteins, Enzymes, Biological Buffers, Substrates, Others), By Technology (Molecular Diagnostics, Clinical Chemistry, Immunochemistry, Others), By End User (Diagnostic Laboratories, Pharmaceutical & Biotechnological Companies, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Report Code: SRPH55261DR
Author : Debashree Bora
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global IVD Raw Materials Market Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Antibody
        1. By Value
      3. Antigens
        1. By Value
      4. Proteins
        1. By Value
      5. Enzymes
        1. By Value
      6. Biological Buffers
        1. By Value
      7. Substrates
        1. By Value
      8. Others
        1. By Value
    3. By Technology
      1. Introduction
        1. Technology By Value
      2. Molecular Diagnostics
        1. By Value
      3. Clinical Chemistry
        1. By Value
      4. Immunochemistry
        1. By Value
      5. Others
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Diagnostic Laboratories
        1. By Value
      3. Pharmaceutical & Biotechnological Companies
        1. By Value
      4. Others
        1. By Value
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Antibody
        1. By Value
      3. Antigens
        1. By Value
      4. Proteins
        1. By Value
      5. Enzymes
        1. By Value
      6. Biological Buffers
        1. By Value
      7. Substrates
        1. By Value
      8. Others
        1. By Value
    3. By Technology
      1. Introduction
        1. Technology By Value
      2. Molecular Diagnostics
        1. By Value
      3. Clinical Chemistry
        1. By Value
      4. Immunochemistry
        1. By Value
      5. Others
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Diagnostic Laboratories
        1. By Value
      3. Pharmaceutical & Biotechnological Companies
        1. By Value
      4. Others
        1. By Value
    5. U.S.
      1. By Product
        1. Introduction
          1. Product By Value
        2. Antibody
          1. By Value
        3. Antigens
          1. By Value
        4. Proteins
          1. By Value
        5. Enzymes
          1. By Value
        6. Biological Buffers
          1. By Value
        7. Substrates
          1. By Value
        8. Others
          1. By Value
      2. By Technology
        1. Introduction
          1. Technology By Value
        2. Molecular Diagnostics
          1. By Value
        3. Clinical Chemistry
          1. By Value
        4. Immunochemistry
          1. By Value
        5. Others
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Diagnostic Laboratories
          1. By Value
        3. Pharmaceutical & Biotechnological Companies
          1. By Value
        4. Others
          1. By Value
    6. Canada
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Antibody
        1. By Value
      3. Antigens
        1. By Value
      4. Proteins
        1. By Value
      5. Enzymes
        1. By Value
      6. Biological Buffers
        1. By Value
      7. Substrates
        1. By Value
      8. Others
        1. By Value
    3. By Technology
      1. Introduction
        1. Technology By Value
      2. Molecular Diagnostics
        1. By Value
      3. Clinical Chemistry
        1. By Value
      4. Immunochemistry
        1. By Value
      5. Others
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Diagnostic Laboratories
        1. By Value
      3. Pharmaceutical & Biotechnological Companies
        1. By Value
      4. Others
        1. By Value
    5. U.K.
      1. By Product
        1. Introduction
          1. Product By Value
        2. Antibody
          1. By Value
        3. Antigens
          1. By Value
        4. Proteins
          1. By Value
        5. Enzymes
          1. By Value
        6. Biological Buffers
          1. By Value
        7. Substrates
          1. By Value
        8. Others
          1. By Value
      2. By Technology
        1. Introduction
          1. Technology By Value
        2. Molecular Diagnostics
          1. By Value
        3. Clinical Chemistry
          1. By Value
        4. Immunochemistry
          1. By Value
        5. Others
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Diagnostic Laboratories
          1. By Value
        3. Pharmaceutical & Biotechnological Companies
          1. By Value
        4. Others
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest of Europe
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Antibody
        1. By Value
      3. Antigens
        1. By Value
      4. Proteins
        1. By Value
      5. Enzymes
        1. By Value
      6. Biological Buffers
        1. By Value
      7. Substrates
        1. By Value
      8. Others
        1. By Value
    3. By Technology
      1. Introduction
        1. Technology By Value
      2. Molecular Diagnostics
        1. By Value
      3. Clinical Chemistry
        1. By Value
      4. Immunochemistry
        1. By Value
      5. Others
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Diagnostic Laboratories
        1. By Value
      3. Pharmaceutical & Biotechnological Companies
        1. By Value
      4. Others
        1. By Value
    5. China
      1. By Product
        1. Introduction
          1. Product By Value
        2. Antibody
          1. By Value
        3. Antigens
          1. By Value
        4. Proteins
          1. By Value
        5. Enzymes
          1. By Value
        6. Biological Buffers
          1. By Value
        7. Substrates
          1. By Value
        8. Others
          1. By Value
      2. By Technology
        1. Introduction
          1. Technology By Value
        2. Molecular Diagnostics
          1. By Value
        3. Clinical Chemistry
          1. By Value
        4. Immunochemistry
          1. By Value
        5. Others
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Diagnostic Laboratories
          1. By Value
        3. Pharmaceutical & Biotechnological Companies
          1. By Value
        4. Others
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Singapore
    11. Taiwan
    12. South East Asia
    13. Rest of Asia-Pacific
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Antibody
        1. By Value
      3. Antigens
        1. By Value
      4. Proteins
        1. By Value
      5. Enzymes
        1. By Value
      6. Biological Buffers
        1. By Value
      7. Substrates
        1. By Value
      8. Others
        1. By Value
    3. By Technology
      1. Introduction
        1. Technology By Value
      2. Molecular Diagnostics
        1. By Value
      3. Clinical Chemistry
        1. By Value
      4. Immunochemistry
        1. By Value
      5. Others
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Diagnostic Laboratories
        1. By Value
      3. Pharmaceutical & Biotechnological Companies
        1. By Value
      4. Others
        1. By Value
    5. UAE
      1. By Product
        1. Introduction
          1. Product By Value
        2. Antibody
          1. By Value
        3. Antigens
          1. By Value
        4. Proteins
          1. By Value
        5. Enzymes
          1. By Value
        6. Biological Buffers
          1. By Value
        7. Substrates
          1. By Value
        8. Others
          1. By Value
      2. By Technology
        1. Introduction
          1. Technology By Value
        2. Molecular Diagnostics
          1. By Value
        3. Clinical Chemistry
          1. By Value
        4. Immunochemistry
          1. By Value
        5. Others
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Diagnostic Laboratories
          1. By Value
        3. Pharmaceutical & Biotechnological Companies
          1. By Value
        4. Others
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest of MEA
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Antibody
        1. By Value
      3. Antigens
        1. By Value
      4. Proteins
        1. By Value
      5. Enzymes
        1. By Value
      6. Biological Buffers
        1. By Value
      7. Substrates
        1. By Value
      8. Others
        1. By Value
    3. By Technology
      1. Introduction
        1. Technology By Value
      2. Molecular Diagnostics
        1. By Value
      3. Clinical Chemistry
        1. By Value
      4. Immunochemistry
        1. By Value
      5. Others
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Diagnostic Laboratories
        1. By Value
      3. Pharmaceutical & Biotechnological Companies
        1. By Value
      4. Others
        1. By Value
    5. Brazil
      1. By Product
        1. Introduction
          1. Product By Value
        2. Antibody
          1. By Value
        3. Antigens
          1. By Value
        4. Proteins
          1. By Value
        5. Enzymes
          1. By Value
        6. Biological Buffers
          1. By Value
        7. Substrates
          1. By Value
        8. Others
          1. By Value
      2. By Technology
        1. Introduction
          1. Technology By Value
        2. Molecular Diagnostics
          1. By Value
        3. Clinical Chemistry
          1. By Value
        4. Immunochemistry
          1. By Value
        5. Others
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Diagnostic Laboratories
          1. By Value
        3. Pharmaceutical & Biotechnological Companies
          1. By Value
        4. Others
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest of LATAM
    1. IVD Raw Materials Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Creative Diagnostics
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Merck KGaA
    3. Thermo Fisher Scientfic Inc
    4. OYC Americas, Inc.
    5. Fapon Biotech Inc.
    6. Biosynth
    7. Hoffmann-La Roche Ltd
    8. Sysmex Corporation
    9. Shenzhen AIVD Biotechnology Co., Ltd.
    10. Glentham Life Sciences Limited
    11. Neogen Corporation
    12. MP Biomedicals
    13. Angstrom Biotech
    14. SR Bioera
    15. Bio-Rad Laboratories
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Armor Materials Market Size The global Armor Materials Market Size was valued at USD 17.43 billion in 2024 and is projected to reach from USD 18.55 billion in 2025 to USD 30.47 billion by 2033, growing at a CAGR of 6.4%
Buy Now
Global Report
The global biomaterials market size was valued at USD 106.51 billion in 2022. It is estimated to reach USD 619.27 billion by 2031, growing at a CAGR of 15.8% during the forecast period (2023–2031). A biomaterial is a substance design
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.